Driven by a consolidation of offerings, the number of Part D prescription drug plans will decrease by 14% in 2015. While monthly premiums will decrease overall by 2%, there will be large premium variations.
Driven by a consolidation of offerings, the number of Part D prescription drug plans will decrease by 14% in 2015, according to Avalere Health’s analysis of CMS’ filings for 2015.
Plan sponsors will rely on more highly managed plan products. The number of health maintenance organization plans will increase 1.5%, while the number of preferred provider organizations will decrease by nearly 9% from 2014 to 2015.
Top plan sponsors like Aetna, Cigna, CVS, and UnitedHealth are driving the prescription drug plan reduction by consolidating their offerings. As a result, the average monthly premiums for these drug plans will decrease by 2% from $39.88 in 2014 to $38.95 as a large number of beneficiaries are shifted into lower-cost plans, according to Avalere’s calculations.
Avalere warns about large premium variations. Aetna’s new Medicare Rx Saver plan reduces premiums by more than 30%, but WellCare’s Classic plan is increasing premiums by more than 50%. However, overall, half of the top 10 prescription drug plans will have average premiums lower than $30.
“When seniors choose a prescription drug plan for 2015, they should carefully look at their options to select the plan that best meets their health and financial needs,” Christine Harhaj, senior manager at Avalere Health, said in a statement. “While beneficiaries will welcome lower premiums, they will need to look at other facets of benefit design including how their medications are covered, cost sharing responsibilities, and total out-of-pocket spending.”
In 2015, 42% of drug plans will have $0 deductibles, a decline from 47% in 2014. Additionally, roughly three-quarters of plans will not cover drugs in the Part D coverage gap next year.
The number of plans participating in Medicare Advantage will also decline 3% to 2,450 in 2015 from 2,527 in 2014. The regions that will see the most sizeable plan withdrawals are high-population density areas in the Southeast and the Mid-Atlantic.
“To succeed in the market today, Medicare health plans need to be efficient, reasonably priced, and focused on quality metrics,” Dan Mendelson, chief executive officer of Avalere Health, said in a statement. “There will inevitably be some plans that can’t survive in this demanding environment, and others that enter precisely because their operations are prepared to meet the challenge of public programs.”
Prices for care at hospital trauma centers vary across hospitals; drug shortages reached a record high during the first quarter of 2024; although 3 of the biggest makers of asthma inhalers pledged to cap out-of-pocket costs for some US patients at $35, these do not apply to daily inhalers used by the youngest kids with asthma.
Read More
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
The Biden administration recently launched the Global Health Security Strategy, a new effort to combat the spread of infectious diseases; lawmakers zeroed in on the risks of massive consolidation in health care during the first congressional hearing on the Change Healthcare hack; the FDA recently announced the recall of a pair of heart devices linked to numerous deaths and injuries.
Read More
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen